Nektar Therapeutics (NKTR) Restructuring Costs (2022 - 2023)
Nektar Therapeutics (NKTR) recorded quarterly Restructuring Costs of $1.9 million in Q4 2023, up 189.26% quarter-over-quarter from $652000.0 in Q3 2023, and down 31.54% on a YoY basis from $2.8 million in Q4 2022.
Nektar Therapeutics (NKTR) Restructuring Costs (2022 - 2023) Analysis & Trends
Nektar Therapeutics' Restructuring Costs history runs 2 years deep, the most recent figure standing at $1.9 million for Q4 2023.
- In Q4 2023, Restructuring Costs fell 31.54% year-over-year to $1.9 million; the TTM figure through Sep 2024 stood at $1.9 million (down 70.35% YoY), while the FY2023 annual figure was $5.5 million, down 82.67% from the prior year.
- Restructuring Costs was $1.9 million for Q4 2023 at Nektar Therapeutics, up from $652000.0 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $27.8 million in Q2 2022 to a low of $652000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Nektar Therapeutics | 1.51 Bn | 939.55 Mn | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.89 Mn |
| Sep 30, 2023 | 652,000.00 |
| Jun 30, 2023 | 1.36 Mn |
| Mar 31, 2023 | 1.60 Mn |
| Dec 31, 2022 | 2.76 Mn |
| Sep 30, 2022 | 8.53 Mn |
| Jun 30, 2022 | 27.75 Mn |
| Mar 31, 2022 | 1.48 Mn |